Search our Database of Scientific Publications and Authors

I’m looking for a

    6866 results match your criteria Thyroid Medullary Carcinoma

    1 OF 138

    THE PENETRANCE OF MEN2 PHEOCHROMOCYTOMA IS NOT ONLY DETERMINED BY RET MUTATIONS.
    Endocr Relat Cancer 2017 Jun 25. Epub 2017 Jun 25.
    H Neumann, Medizinische Klinik IV, Sektion Präventive Medizin, Universitätsklinikum Freiburg, Freiburg i.Br., Germany.
    Multiple endocrine neoplasia type 2A (MEN2A) is a rare syndrome which main component is medullary thyroid carcinoma (MTC). The natural history of MTC is mainly determined by RET mutations. The second main component of MEN2A is pheochromocytoma. Read More

    Analysis of Newly Identified and Rare Synonymous Genetic Variants in the RET Gene in Patients with Medullary Thyroid Carcinoma in Polish Population.
    Endocr Pathol 2017 Jun 24. Epub 2017 Jun 24.
    Department of Immunology, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland.
    Gain-of-function germline mutations of the RET proto-oncogene are responsible for initiation of carcinogenesis within the thyroid gland and development of hereditary form of medullary thyroid carcinoma and MEN2 syndrome. Genotype-phenotype correlations are established for most RET mutations, but the importance of the synonymous changes in this gene remains debatable. We aimed to analyze RET gene variants in Polish population. Read More

    Diagnostic utility of PET/CT with (18)F-DOPA and (18)F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff.
    Eur J Nucl Med Mol Imaging 2017 Jun 23. Epub 2017 Jun 23.
    Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Virgen del Rocío, Seville, Spain.
    Purpose: This study sought to evaluate and compare the utility of 18-F-fluorodihydroxyphenylalanine ((18)F-DOPA) and 18-F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography/computed tomography (PET/CT) for identification of lesions in patients with recurrent medullary thyroid carcinoma (MTC). In addition, we analyzed the correlation between the calcitonin (Ct), carcinoembryonic antigen (CEA) levels, each doubling time (DT), and PET positivity. We evaluated the reliability of the 150 pg/mL Ct cutoff set by the American Thyroid Association guidelines for further imaging (including (18)F-DOPA PET/CT). Read More

    C Cell and Follicular Epithelial Cell Precursor Lesions of the Thyroid.
    Arch Pathol Lab Med 2017 Jun 23. Epub 2017 Jun 23.
    Context: - The identification of precursor or dysplastic lesions in the thyroid is difficult. Pathology of the C cell has been extensively studied, and the preneoplastic nature of C-cell hyperplasia in the setting of familial medullary thyroid carcinomas is well established. However, the distinction between neoplastic and physiologic/reactive C-cell hyperplasia remains a challenge. Read More

    Cushing Syndrome: Diagnostic Workup and Imaging Features, With Clinical and Pathologic Correlation.
    AJR Am J Roentgenol 2017 Jul;209(1):19-32
    1 Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030.
    Objective: Cushing syndrome (CS) is a constellation of clinical signs and symptoms resulting from chronic exposure to excess cortisol, either exogenous or endogenous. Exogenous CS is most commonly caused by administration of glucocorticoids. Endogenous CS is subdivided into two types: adrenocorticotropic hormone (ACTH) dependent and ACTH independent. Read More

    Discovery of novel wtRET and V804MRET inhibitors: from hit to lead.
    ChemMedChem 2017 Jun 22. Epub 2017 Jun 22.
    University of Padova, Pharmaceutical Sciences, via Marzolo 5, I-35131, Padova, ITALY.
    Oncogenic activation of the RET kinase has been found in several neoplastic diseases, like medullary thyroid carcinoma, multiple endocrine neoplasia, papillary thyroid carcinoma and non-small cells lung cancer. Currently approved RET inhibitors were not originally designed to be RET inhibitors and their potency against RET kinase has not been optimized. Hence, novel compounds able to inhibit both wtRET and its mutants (e. Read More

    Sorafenib in Japanese Patients With Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Thyroid 2017 Jun 21. Epub 2017 Jun 21.
    Bayer Yakuhin, Ltd., 8Medical Affairs, Oncology and Hematology, and Clinical Development, Specialty Medicine, Tokyo, Japan ;
    Background: Therapeutic options for treating advanced or metastatic medullary thyroid carcinoma (MTC) and anaplastic thyroid carcinoma (ATC) are still limited in Japan even though vandetanib for MTC, and lenvatinib for MTC and ATC have been approved. Sorafenib is an oral multikinase inhibitor approved for the treatment of patients with radioactive iodine-refractory (RAI-R) differentiated thyroid cancer (DTC). We conducted an uncontrolled, open-label, multicenter, single-arm, phase 2 clinical study to evaluate the safety and efficacy of sorafenib in Japanese patients with MTC and ATC. Read More

    Assessment of cabozantinib treatment on QT interval in a phase 3 study in medullary thyroid cancer: evaluation of indirect QT effects mediated through treatment-induced changes in serum electrolytes.
    Cancer Chemother Pharmacol 2017 Jun 20. Epub 2017 Jun 20.
    Exelixis Inc., 210 East Grand Avenue, South San Francisco, CA, 94080-0511, USA.
    Purpose: This study evaluated factors impacting QTc interval in a phase 3 trial of cabozantinib in progressive, metastatic, medullary thyroid cancer (MTC).

    Methods: Electrocardiogram (12-lead ECG) measurements were obtained at screening, and at pre-dose, and 2, 4, and 6 h post-dose on Days 1 and 29 in a phase 3 study in patients with MTC treated with cabozantinib (140 mg/day). Central tendency analyses were conducted on baseline-corrected QTc values. Read More

    Cabozantinib for the treatment of kidney cancer.
    Expert Rev Anticancer Ther 2017 Jul;17(7):577-584
    a Department of Oncology , Wayne State University/Barbara Ann Karmanos Cancer Institute , Detroit , MI , USA.
    Introduction: Cabozantinib is a small molecule tyrosine kinase inhibitor that initially showed activity in medullary thyroid cancer and was recently approved by the Food and Drug Administration for the treatment of metastatic renal cell carcinoma after progression on first line therapy. Areas covered: In the METEOR trial, cabozantinib demonstrated significantly improved efficacy in all three endpoints; response rates, progression free survival and overall survival in a randomized trial with everolimus as an active comparator. Cabozantinib also showed activity in the front line setting in RCC within the CABOSUN trial. Read More

    Value of 99mTc-MIBI SPECT/CT parathyroid imaging and ultrasonography for concomitant thyroid carcinoma.
    Nucl Med Commun 2017 Jun 13. Epub 2017 Jun 13.
    Departments of aNuclear Medicine bEndocrine and Metabolic Diseases, Rui Jin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
    Purpose: We aimed to assess the frequency of carcinoma in cases with suspected parathyroid adenoma and test the value of Tc-methoxyisobutylisonitrile (Tc-MIBI) single-photon emission computed tomography/computed tomography (SPECT/CT) parathyroid imaging and neck ultrasonography in detecting concomitant thyroid carcinoma.

    Patients And Methods: We enrolled 741 patients with clinically suspected parathyroid adenoma who underwent Tc-MIBI planer scans and SPECT/CT of the skull base, neck, and thorax; patients also underwent ultrasonography within 1 month before SPECT/CT. Each case with suspected lesion was analyzed and correlated with pathology. Read More

    THE COMBINED USE OF CALCITONIN DOUBLING TIME AND (18)F-FDG PET/CT IMPROVES PROGNOSTIC VALUES IN MEDULLARY THYROID CARCINOMA: THE CLINICAL UTILITY OF (18)F-FDG PET/CT.
    Endocr Pract 2017 Jun 14. Epub 2017 Jun 14.
    From: 1Multiple Endocrine Neoplasia Outpatient Clinic and Laboratory of Molecular and Translational Endocrinology, Division of Endocrinology, Department of Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, 04039-032, Brazil.
    Objective: Calcitonin and carcinoembryonic antigen (CEA) doubling times are established prognostic markers in medullary thyroid cancer (MTC). On the other hand, positron emission tomography with fluorine-18 fluorodeoxyglucose ((18)F-FDG PET/CT) shows an increased rate of detection with high blood tumor marker levels in several cancers. This study aims to analyze the ability of (18)F-FDG PET/CT to determine prognosis in the followup of patients with MTC. Read More

    ECTOPIC CUSHING'S SYNDROME: A TEN YEAR EXPERIENCE FROM A TERTIARY CARE CENTRE IN SOUTHERN INDIA.
    Endocr Pract 2017 Jun 14. Epub 2017 Jun 14.
    = equal contribution.
    Objective: Ectopic ACTH secretion is a less common cause of Cushing's syndrome, and is seen in 5 to 10% of cases with endogenous hypercortisolemia. We hereby describe our experience of patients with ectopic ACTH syndrome, who have been managed over the past 10 years at a tertiary care centre in Southern India.

    Methods: The inpatient and outpatient records of patients from 2006 to 2015 were retrospectively reviewed. Read More

    Medullary Thyroid Carcinoma in MEN2A: ATA Moderate or High-Risk RET Mutations Do Not Predict Disease Aggressiveness
    J Clin Endocrinol Metab 2017 05 9. Epub 2017 May 9.
    Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX
    Context: High-risk RET mutations (codon 634) are associated with earlier development of medullary thyroid carcinoma (MTC) and presumed increased aggressiveness compared with moderate-risk RET mutations.

    Objective: To determine if high-risk RET mutations are more aggressive

    Design: Retrospective cohort study utilizing institutional MEN2 registry

    Setting: A tertiary cancer care center

    Patients: Those with MTC and moderate- or high-risk germline RET mutation.

    Intervention: None (observational study)

    Main Outcome Measures: Proxies for aggressiveness were: overall survival (OS) and time to distant metastatic disease (DMD)

    Results: 127 moderate-risk and 135 high-risk patients were included (n=262). Read More

    Phaeochromocytoma in multiple endocrine neoplasia type 2: RET codon-specific penetrance and changes in management during the last four decades.
    Clin Endocrinol (Oxf) 2017 Jun 12. Epub 2017 Jun 12.
    Endocrine Practice, Heidelberg, Germany.
    Objectives: We describe phaeochromocytoma penetrance in multiple endocrine neoplasia type 2 (MEN2) according to RET protooncogene-specific mutations, and report changes in phaeochromocytoma diagnosis and management from 1968 to 2015.

    Design: This retrospective chart review included 309 MEN2 patients from one specialised ambulatory care centre. Phaeochromocytoma patients were categorised by diagnosis date: early, 1968-1996, n = 40; and recent, 1997-2015, n = 45. Read More

    Laryngeal chondrosarcoma mimicking medullary thyroid carcinoma on fine-needle aspiration cytology: A case report of a diagnostic pitfall.
    Diagn Cytopathol 2017 Jun 11. Epub 2017 Jun 11.
    Department of Pathology and Laboratory Medicine, University of Minnesota, Minneapolis, Minnesota.
    Chondrosarcoma (CS) of larynx is a rare laryngeal tumor accounting about 1% of laryngeal malignancies. When CS arises from thyroid cartilage, it may clinically present as a thyroid nodule. Here we report a rare case of CS of thyroid cartilage misinterpreted as medullary thyroid carcinoma. Read More

    Lymph Node Metastases in Papillary and Medullary Thyroid Carcinoma Are Independent of Intratumoral Lymphatic Vessel Density.
    Eur Thyroid J 2017 Apr 17;6(2):57-64. Epub 2017 Mar 17.
    Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal.
    Background: Blood and lymph vessel invasion are well-recognized markers of tumor aggressiveness, as these are the routes that lead to metastases. Thyroid tumors, depending on the histological variant, tend to have distinctive biological behaviors and use different vascular routes to metastasize, yet the mechanisms underlying the metastatic process are still poorly understood.

    Objectives: The aim of this study was to assess how the lymph vessel density (LVD) in different histological types of thyroid tumors, and in their surrounding tissue, correlate with the presence of lymph node metastases (LNM) and tumor pathological features. Read More

    The value of 18F-DOPA PET/CT in patients with medullary thyroid carcinoma and increased calcitonin values.
    Nucl Med Commun 2017 Jul;38(7):636-641
    aDepartment of Nuclear Medicine and Radiation Protection, University Hospital Centre Zagreb bSchool of Medicine, University of Zagreb, Zagreb, Croatia.
    Aim: The aim of this prospective observational study was to examine the benefit of a fluorine-18-L-dihydroxyphenylalanine (F-DOPA) PET/computed tomography (CT) scan in patients with medullary thyroid carcinoma (MTC) in terms of increased calcitonin levels.

    Patients And Methods: Twenty-eight MTC patients after initial total thyreoidectomy with increasing follow-up calcitonin levels suggestive for active disease after negative conventional imaging findings (neck ultrasound or thorax, abdomen, pelvis multislice computed tomography as standard imaging) were scanned using F-DOPA PET/CT from November 2012 to April 2016. The mean calcitonin level was 108. Read More

    Comparison of the prognostic values of selected inflammation based scores in patients with medullary thyroid carcinoma: A pilot study.
    J Surg Oncol 2017 May 29. Epub 2017 May 29.
    Thyroid and Parathyroid Surgery Center, West China Hospital, Sichuan University, Chengdu, China.
    Background: The significance of inflammation based scores including the neutrophil-to-lymphocyte ratio (NLR), derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), prognostic nutritional index (PNI), and plasma fibrinogen remains unclear in medullary thyroid carcinoma (MTC). We aimed to compare the prognostic value of these scores.

    Methods: Seventy-eight patients newly diagnosed as MTC with operation in our institution from May 2009 to September 2016 were retrospectively evaluated. Read More

    Incidental Detection of Synchronous Medullary Thyroid Carcinoma with Bilateral Adrenal Pheochromocytoma on Iodine-123 Metaiodobenzylguanidine Scintigraphy, Leading to Diagnosis of Multiple Endocrine Neoplasia 2A.
    World J Nucl Med 2017 Apr-Jun;16(2):169-171
    Department of Nuclear Medicine and Molecular Imaging, University at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York, USA.
    We report a case of a 29-year-old female with the family history of medullary thyroid carcinoma (MTC) presenting with hematuria and tachycardia, who was found to have bilateral adrenal masses on abdominal computed tomography and biochemical testing compatible with pheochromocytoma. Iodine-123 (I-123) metaiodobenzylguanidine (MIBG) scintigraphy for preoperative planning prior to planned adrenalectomy revealed incidental synchronous unifocal MTC, along with expected bilateral adrenal pheochromocytomas. Pathology confirmed these findings, and subsequent genetic testing confirmed a rearranged during transfection proto-oncogene mutation on exon 11, confirming the clinical diagnosis of multiple endocrine neoplasia 2A (MEN 2A). Read More

    Clinical and pathological analysis of 19 cases of medullary thyroid carcinoma without an increase in calcitonin.
    Exp Toxicol Pathol 2017 May 25. Epub 2017 May 25.
    Zhejiang Cancer Hospital, Hangzhou 310000, Zhejiang, China. Electronic address:
    Background: Medullary thyroid carcinoma (MTC), defined as a malignant tumour with C-cell differentiation, is of neuroendocrine origin and is characterized by the synthesis and secretion of calcitonin (CT). MTC without CT secretion has been reported on rare occasions. The purpose of this study was to evaluate the histological, immunohistochemical, and molecular pathologic features as well as the clinical significance of non-secretory MTC (NCR-MTC). Read More

    A study of FoxA1 expression in thyroid tumors.
    Hum Pathol 2017 May 22. Epub 2017 May 22.
    Department of Histopathology, The Christie NHS Foundation Trust, Manchester, UK; Institute of Cancer Sciences, The University of Manchester, Manchester, UK. Electronic address:
    FoxA1 regulates a variety of tissues during embryogenesis and early life. In thyroid, FoxA1 expression has recently been shown in C cells and medullary thyroid carcinomas but not in follicular cells. FoxA1 has also been proposed as potential oncogene in anaplastic thyroid carcinomas. Read More

    Expression of MicroRNAs in Thyroid Carcinoma.
    Methods Mol Biol 2017 ;1617:261-280
    School of Computing, University of South Alabama, Mobile, AL, 36688, USA.
    MicroRNA (miRNA) are negative regulators of gene expression and subsequent protein production. This method of action translates into regulatory control over cellular processes, including development, signaling, metabolism, and apoptosis. A broad range of miRNA are shown to have abnormal expressions in thyroid cancers which could explain the pathology of tumor oncogenesis and disease progression. Read More

    A nodule on the scalp as the first sign of extranodal disease in medullary thyroid carcinoma.
    Dermatol Online J 2017 May 15;23(5). Epub 2017 May 15.
    Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain.
    Medullary carcinoma of the thyroid gland accounts for only 5-10% of thyroid carcinomas. Also, metastases to the skin of malignant tumors are infrequently (2-9% of patients). In the case herein reported in a 64-year old woman, a metastatic nodule on the scalp was the presenting clinical manifestation of a medullary thyroid carcinoma. Read More

    Can Medullary Thyroid Carcinoma Arise in Thyroglossal Duct Cysts? A Search for Parafollicular C-cells in 41 Resected Cases.
    Head Neck Pathol 2017 May 23. Epub 2017 May 23.
    Department of Anatomic Pathology, University of Pittsburgh Medical Center, 3459 Fifth ave suite E-733, Pittsburgh, PA, USA.
    Thyroglossal duct cysts (TGDCs) are present in ~7% of adults and develop from the midline migratory tract between the foramen cecum and anatomic location of the thyroid. Thyroid tissue can be identified in 2/3 of TGDCs, and up to 1% develop associated malignancy, 90% of which are papillary thyroid carcinoma. Cases of follicular and anaplastic carcinoma have been documented, but there are no reports of medullary thyroid carcinoma arising in a TGDC. Read More

    Expression of claudin 1, 4 and 7 in thyroid neoplasms.
    Oncol Lett 2017 May 27;13(5):3722-3726. Epub 2017 Mar 27.
    Department of Pathology, University of Health Sciences, Antalya Education and Research Hospital, Antalya 07050, Turkey.
    The distinction of thyroid carcinoma from benign thyroid neoplasm, as well as the subtyping of papillary carcinoma (PC) and follicular carcinoma (FC), may be performed histopathologically in the majority of cases. However, in certain cases, it is difficult to histopathologically distinguish between PC and FC, as well as follicular adenoma (FA), FC and the dominant nodule of multinodular goiter (MNG-DN). The present study aimed to determine the roles of the expression levels of the tight junction proteins claudin 1, 4 and 7 in the differential diagnosis of PC, FC, FA, MNG-DN, medullary carcinoma (MC) and anaplastic carcinoma (AC). Read More

    Timing and extension of lymphadenectomy in medullary thyroid carcinoma: A case series from a single institution.
    Int J Surg 2017 May;41 Suppl 1:S70-S74
    University of Perugia, Medical School, Endocrine Surgery Unit, S. Maria University Hospital, Terni, Italy. Electronic address:
    Background: Medullary thyroid carcinoma is an aggressive tumor and presents with significant morbidity and mortality and a high rate of lymph node metastases. The combination of total thyroidectomy and cervical lymphadenectomy is the essential treatment for those patients presenting with cervical lymph node metastases.

    Materials And Methods: A retrospective analysis of 117 patients operated for medullary thyroid carcinoma over a period of 15 years at a single institution. Read More

    Genetics of medullary thyroid cancer: An overview.
    Int J Surg 2017 May;41 Suppl 1:S2-S6
    Department of Neurological, Metabolic and Geriatric Science, University of Campania "Luigi Vanvitelli", Naples, Italy. Electronic address:
    Medullary thyroid carcinoma (MTC) represents 3-5% of thyroid cancers. 75% is sporadic and 25% is the dominant component of the hereditary multiple endocrine neoplasia (MEN) type 2 syndromes. Three different subtypes of MEN2, such as MEN2A, MEN2B, and Familial MTC (FMTC) have been defined, based on presence or absence of hyperparathyroidism, pheocromocytoma and characteristic clinical features. Read More

    Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative.
    Int J Oncol 2017 Jul 11;51(1):145-157. Epub 2017 May 11.
    College of Pharmacy, University of Arizona, Tucson, AZ 85719, USA.
    Dominant-activating mutations in the RET (rearranged during transfection) proto-oncogene, which encodes a receptor tyrosine kinase, is often associated with the development of medullary thyroid carcinoma (MTC). The proximal promoter region of the RET gene consists of a guanine-rich sequence containing five runs of three consecutive guanine residues that serve as the binding site for transcriptional factors. As we have recently shown, this stretch of nucleotides in the promoter region is highly dynamic in nature and tend to form non-B DNA secondary structures called G-quadruplexes, which suppress the transcription of the RET gene. Read More

    Identification of microRNAs associated with medullary thyroid carcinoma by bioinformatics analyses.
    Mol Med Rep 2017 Jun 3;15(6):4266-4272. Epub 2017 May 3.
    Department of Otorhinolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, P.R. China.
    The present study aimed to investigate the microRNA (miRNA) profile in human medullary thyroid carcinoma (MTC) tissue. The GSE40807 data profile was downloaded from the Gene Expression Omnibus database. Following preprocessing, differentially expressed microRNAs (DEMs) between MTC and healthy tissues were identified. Read More

    [Cabozantinib: Mechanism of action, efficacy and indications].
    Bull Cancer 2017 May 3;104(5):393-401. Epub 2017 May 3.
    Institut Bergonié, centre de lutte contre le cancer de Bordeaux, 229, cours de l'Argonne, 33076 Bordeaux cedex, France.
    Cabozantinib is an oral multiple tyrosine kinase receptor inhibitor (ITK): VEGFR2, c-MET and RET. Inhibition of VEGFR and c-MET decrease resistance of VEGFR inhibitor via c-MET axis. Cabozantinib improve progression-free survival (PFS) in progressive metastatic medullary thyroid cancer (MTC): 4 months in the placebo group and 11. Read More

    Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cells.
    Cancer Biol Ther 2017 May 5:1-11. Epub 2017 May 5.
    a Department of Biochemistry , Medical College of Wisconsin , Milwaukee , WI , USA.
    Although the FDA-approved receptor tyrosine kinases inhibitors, vandetanib and cabozantinib, are used to treat surgically inoperable progressive medullary thyroid carcinoma (MTC), not all patients are responsive while the disease sometimes progresses after an initial response. To better understand MTC drug resistance at molecular and biochemical levels, we have generated drug-resistant subpopulations of the human MTC cell lines, TT and MZ-CRC-1, via prolonged exposure to vandetanib and cabozantinib. These drug-resistant progenies exhibited substantial cross-resistance to vandetanib and cabozantinib, suggesting that these inhibitors may invoke an overlapping resistance mechanism(s) in MTC cells. Read More

    Clinical characteristics and treatment of thyroid cancer in children and adolescents: a retrospective analysis of 83 patients.
    J Zhejiang Univ Sci B 2017 May;18(5):430-436
    Department of Head and Neck Surgery, Zhejiang Cancer Hospital, Hangzhou 310011, China.
    Objective: To study the clinical characteristics, treatment, and prognosis of thyroid cancer in children and adolescents.

    Methods: We performed a retrospective analysis of clinical data from 83 cases of thyroid cancer in children and adolescents from January 1990 to December 2010. We compared extra-thyroid extension, lymph node metastasis, distant metastasis, and prognosis between pediatric patients ≤12 years of age (27 cases) and those >12 years of age (56 cases). Read More

    Genotype-Phenotype Correlation in Patients With Germline Mutations of VHL, RET, SDHB, and SDHD Genes: Thai Experience.
    Clin Med Insights Endocrinol Diabetes 2017 20;10:1179551417705122. Epub 2017 Apr 20.
    Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
    Mutations in the VHL, RET, SDHB, and SDHD genes are responsible for von Hippel-Lindau (VHL) disease, multiple endocrine neoplasia type 2 (MEN2), and familial paraganglioma, respectively. However, genotype-phenotype correlation data are lacking in Southeast Asia. A retrospective medical chart review was performed on patients referred to the genetics service. Read More

    Ultrasonographic characteristics of medullary thyroid carcinoma: a comparison with papillary thyroid carcinoma.
    Oncotarget 2017 Apr;8(16):27520-27528
    Department of Ultrasound, Yantai Hospital of Traditional Chinese Medicine, Yantai, Shandong, China.
    This study was designed to explore differences in the ultrasonographic characteristics of medullary thyroid carcinoma (MTC) and papillary thyroid carcinoma (PTC). This study included 35 cases of MTC and 96 cases of PTC that were surgically and pathologically confirmed. Preoperative ultrasound images were retrospectively reviewed by two physicians (with 5 years' experience in thyroid ultrasound) under the premise of unknown pathological results. Read More

    Surgical approaches in hereditary endocrine tumors.
    Updates Surg 2017 Apr 28. Epub 2017 Apr 28.
    Minimally Invasive Endocrine Surgery Unit, Department of Surgery, Oncology and Gastroenterology, University of Padua, Via Giustiniani 2, 35128, Padua, Italy.
    Endocrine tumors of thyroid, adrenal and parathyroid glands may be due to germline and inheritable mutations in 5-30% of patients. Medullary Thyroid Carcinoma, Pheochromocytoma, Paraganglioma, and Familial Primary Hyperparathyroidism are the most frequent entity. Hereditary endocrine tumors usually have a suggestive familial history; they occur earlier than sporadic variants, are multifocal, and have increased recurrence rates. Read More

    Expression of GLP-1 receptor and CD26 in human thyroid C-cells: The association of thyroid C-cell tumorigenesis with incretin-based medicine.
    Oncol Lett 2017 Apr 20;13(4):2684-2690. Epub 2017 Feb 20.
    Department of Endocrinology, The First Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China.
    Recent reports have demonstrated that long-term and high dosage treatments with incretin-based medicine, such as hormone glucagon-like peptide-1 (GLP-1) may induce thyroid C-cell pathological changes in rodents, rather than in humans. Doubts regarding the tumorigenic potential of GLP-1 analogues in human thyroid C-cells remain. The present study aimed to determine the expression levels of GLP-1 receptor (GLP-1R) and cluster of differentiation 26 (CD26) in the C-cells of thyroid tissues from non-neoplastic, medullary carcinoma and hyperplasia subjects, and to explore the potential clinical significance. Read More

    Synergistic activity of everolimus and 5-aza-2'-deoxycytidine in medullary thyroid carcinoma cell lines.
    Mol Oncol 2017 Apr 28. Epub 2017 Apr 28.
    Department of Clinical Sciences and Community Health (DISCCO), University of Milan, Italy.
    Medullary thyroid cancer (MTC) is a tumor highly resistant to chemo- and radiotherapy. Drug resistance can be induced by epigenetic changes such as aberrant DNA methylation. To overcome drug resistance, we explored a promising approach based on the use of 5-aza-2'-deoxycytidine (AZA), a demethylating agent, in combination with the mTOR inhibitor everolimus in MTC cells (MZ-CRC-1 and TT). Read More

    Association between Hashimoto's Thyroiditis and Thyroid Cancer in 64,628 Patients.
    Front Oncol 2017 10;7:53. Epub 2017 Apr 10.
    Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
    Background: The incidence of thyroid cancer (TC) is increasing although explanatory causes are lacking. A link between cancer and inflammation is well documented but unclear for autoimmune thyroid diseases and TC. We aimed to systematically review the association between Hashimoto's thyroiditis (HT) and papillary, follicular, medullary, anaplastic thyroid carcinoma, and thyroid lymphoma (TL). Read More

    [Current situation and thinking of diagnosis and treatment in some types of thyroid cancer].
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2017 Apr;52(4):305-308
    Cancer Molecular Diagnosis Core, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.
    As arising incidence of thyroid cancer, the treatment for thyroid carcinoma is becoming increasingly standardized. But there are different opinions on the treatment for some types of thyroid cancers, including the determination of operative opportunity, surgical method, and follow-up observation plan. There are mainly two categories of patients, namely the patients diagnosed as familial thyroid cancer mutation carriers through family screening, including medullary thyroid carcinoma and familial nonmedullary thyroid carcinoma, and the patients with thyroid microcarcinoma that can be observed after diagnosed by fine needle biopsy cytology. Read More

    Bethesda System for Reporting Thyroid Cytopathology: A three-year study at a tertiary care referral center in Saudi Arabia.
    World J Clin Oncol 2017 Apr;8(2):151-157
    Mohamed Abdulaziz Al Dawish, Asirvatham Alwin Robert, Department of Endocrinology, Prince Sultan Military Medical City, Riyadh 11342, Saudi Arabia.
    Aim: To stratify the malignancy risks in thyroid nodules in a tertiary care referral center using the Bethesda system.

    Methods: From January, 2012 to December, 2014, a retrospective analysis was performed among 1188 patients (15-90 years) who had 1433 thyroid nodules and fine-needle aspiration at Prince Sultan Military Medical City, Saudi Arabia. All thyroid cyto-pathological slides and ultra sound reports were reviewed and classified according to the Bethesda System for Reporting Thyroid Cytopathology. Read More

    The p.G534E variant of HABP2 is not associated with sporadic papillary thyroid carcinoma in a Polish population.
    Oncotarget 2017 Apr 6. Epub 2017 Apr 6.
    Oncology Clinic, Holycross Cancer Centre, Kielce, Poland.
    Thyroid cancer is one of the most frequently diagnosed cancers of the endocrine system. There are no known genetic risk factors for non-medullary thyroid cancer, other than a small number of hereditary syndromes; however, approximately 5% of non-medullary thyroid cancer, designated familial non-medullary thyroid cancer, exhibits heritability. The p. Read More

    (68)Ga-DOTATATE PET/CT in recurrent medullary thyroid carcinoma: a lesion-by-lesion comparison with (111)In-octreotide SPECT/CT and conventional imaging.
    Eur J Nucl Med Mol Imaging 2017 Apr 20. Epub 2017 Apr 20.
    Imaging Department, Hospital Israelita Albert Einstein, Av. Albert Einstein, 627, São Paulo, 05651-901, Brazil.
    Purpose: The aim of this study was to prospectively compare the detection rate of (68)Ga-DOTATATE PET-CT with (111)In-octreotide SPECT-CT and conventional imaging (CI) in medullary thyroid carcinoma (MTC) patients with increased calcitonin (Ctn) levels but negative CI after thyroidectomy.

    Methods: Fifteen patients with raised Ctn levels and/or CI evidence of recurrence underwent (68)Ga-DOTATATE PET-CT, (111)In-octreotide SPECT-CT and CI. Histopathology, CI and biochemical/clinical/imaging follow-up were used as the reference standard. Read More

    Association of NF-κB polymorphisms with clinical outcome of non-medullary thyroid carcinoma.
    Endocr Relat Cancer 2017 Jul 20;24(7):287-298. Epub 2017 Apr 20.
    Department of EndocrinologyIuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
    The NF-κB inflammatory pathway plays a major role in cancer development and clinical progression. Activation of NF-κB signaling is promoted by NFKB1 and inhibited by NFKBIA. The present study aimed to determine the relevance of NFKB1 rs4648068 and NFKBIA rs2233406 genetic variants for non-medullary thyroid cancer (NMTC) susceptibility, progression and clinical outcome. Read More

    Hyalinizing trabecular tumour of the thyroid: fine-needle aspiration cytological diagnosis and correlation with histology.
    J Clin Pathol 2017 Apr 19. Epub 2017 Apr 19.
    Service of Clinical Pathology, Lausanne University Hospital, Institute of Pathology, Lausanne, Switzerland.
    Hyalinizing trabecular tumour (HTT) is a rare thyroid neoplasm of follicular cell origin characterised by a trabecular growth pattern and prominent intratrabecular and intertrabecular hyalinisation. These peculiar histological features allow the prompt recognition of this neoplasm in surgical specimens. However, cytological diagnosis of HTT remains elusive and misleading because of overlapping characteristics with other thyroid tumours, particularly papillary thyroid carcinoma (PTC), medullary thyroid carcinoma (MTC) and the newly described non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). Read More

    1 OF 138